Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma.

Amy A. Mehta,Levi N. Kanu,Shalini Sood-Mendiratta,Richard Quinones,Anjali S Hawkins,Richard A. Lehrer,Kiran Malhotra,Robert Papas,David Hillman,Jacob T. Wilensky,Ahmad A. Aref,Thasarat S. Vajaranant,Deepak P. Edward

Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma.

2021

Amy A. Mehta
Levi N. Kanu
Shalini Sood-Mendiratta
Richard Quinones
Anjali S Hawkins
Richard A. Lehrer
Kiran Malhotra
Robert Papas
David Hillman
Jacob T. Wilensky
Ahmad A. Aref
Thasarat S. Vajaranant
Deepak P. Edward

Purpose:To assess the effectiveness and safety of adjunctive topical netarsudil 0.02% and latanoprostene bunod 0.024% in patients with glaucoma.Methods:A retrospective, multi-center, cohort study o...

Keywords:

in patient
Cohort study
Latanoprostene Bunod
Glaucoma
Internal medicine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations